ADVERTISEMENT

Alpha Ideas 20-20: Acepro Advisors’ Kunj Bansal Bets On Astec Lifesciences. Here’s Why

Astec Lifesciences had swung to profit after demonetisation and introduction of the GST.

Workers sprays weed killer on plants at a soya bean farm in Madhya Pradesh, India (Photographer: Prashanth Vishwanathan/Bloomberg) 
Workers sprays weed killer on plants at a soya bean farm in Madhya Pradesh, India (Photographer: Prashanth Vishwanathan/Bloomberg) 

Astec Lifesciences Ltd. is likely to benefit from growth in demand for agrochemicals in domestic and global markets, according to Kunj Bansal, managing director and chief investment officer at Acepro Advisors.

The company has a competent management and is focusing on capacity expansion and backward integration to reduce the cost of production and dependence on China for raw materials, Bansal said at the Alpha Ideas 20-20 event in Mumbai.

He, however, said revival of China’s capacities and poor southwest monsoon are downsides for the company.

Watch Kunj Bansals entire presentation here:

Disclaimer: The commentary on BloombergQuint represents the view of external experts. Investors are advised to consult a certified financial advisor/planner when making any investments. No views shared on a BloombergQuint program or story or conversation should be construed as personal advice.

Quintillion Business Media Pvt. (BloombergQuint) is not responsible for any risk or loss that might occur as a result of using this information in any way, regardless of your interpretation of the advice.

BloombergQuint’s digital and social media platforms provide views of only SEBI-registered investment advisors/analysts.